
US pharma major Eli Lilly (NYSE: LLY) has expanded its partnership with US biotech company Gate Bioscience to develop oral medicines that eliminate disease-causing proteins, adding one target and an option to select a second.
Gate said the agreement announced October 5 could have a total potential value exceeding $870 million, contingent on milestones. The biotech will receive an undisclosed upfront payment and research funding, with a further payment due if Lilly selects the second target.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze